Quality of Life of Stereotactic Versus Hypofractionated Radiation Therapy for Inoperable Stage I Non-Small Cell Lung Cancer: Results From the LUSTRE Trial
International Journal of Radiation Oncology*Biology*Physics · 2025
DOI: 10.1016/j.ijrobp.2025.11.026 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift International Journal of Radiation Oncology*Biology*Physics, 2025. Verfasst von Qirui Hou und 24 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, McMaster University, Hamilton Ontario, Canada; Juravinski Cancer Centre, McMaster University, Department of Medical Physics, …. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Quality of Life, Lung Neoplasms, Radiosurgery. Die Arbeit nennt 9 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Canadian Cancer Society Research Institute.
Abstract (Originalsprache)
PURPOSE: There is limited evidence on quality-of-life (QoL) outcomes of stereotactic body radiation therapy (SBRT) compared with conventionally hypofractionated radiation therapy (CHRT) in patients with medically inoperable stage I (≤5 cm) non-small cell lung cancer (NSCLC). METHODS AND MATERIALS: This phase 3 randomized trial was conducted across 16 Canadian centers, enrolling patients with medically inoperable stage I (≤5 cm) NSCLC. Participants were randomized in a 2:1 ratio to receive SBRT or CHRT. QoL was assessed over 2 years postrandomization using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 and the lung cancer-specific module 13 (LC-13), evaluating physical, symptom, functional, and social well-being. Differences in QoL between treatment groups at 2 weeks and 2 years were analyzed using linear mixed models, adjusting for baseline scores and stratification variables. RESULTS: Of the 233 patients, 154 received SBRT and 79 received CHRT. At 2 weeks, model estimated mean global health scores were higher in the SBRT group (68.93 vs 64.93), with an estimated mean difference of 4.00 (95% CI 3.12, 4.89, P < .01). At 24 months, global health scores were 59.96 for SBRT and 62.88 for CHRT, with a difference of -2.92, 95% CI: -3.73, -2.11, P < .01). Mean LC-13 symptom scores at 2 weeks were 15.70 for SBRT and 17.11 for CHRT, with a difference of -1.41 (95% CI: -1.87, -0.95, P < .01). Mean difference in LC-13 at 24 months was 0.14 (95% CI: -0.29, 0.57, P = .69). CONCLUSIONS: SBRT offers modest benefit in acute QoL and similar benefit in long-term QoL compared with CHRT in patients with inoperable stage I NSCLC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Oncology, McMaster University, Hamilton Ontario, Canada; Juravinski Cancer Centre, McMaster University, Department of Medical Physics, Hamilton Ontario, Canada.
- Department of Oncology, McMaster University, Hamilton Ontario, Canada; Juravinski Cancer Centre, McMaster University, Department of Medical Physics, Hamilton Ontario, Canada; Department of Oncology, Ontario Clinical Onc…
- Juravinski Cancer Centre, McMaster University, Department of Medical Physics, Hamilton Ontario, Canada.
- Department of Radiation Oncology, Saskatchewan Cancer Agency, University of Saskatchewan, Saskatoon, Saskatchewan, Canada.
- Department of Radiation Oncology, McGill University Health Centre, Montreal, Quebec, Canada.
- Department of Radiation Oncology, McGill University Health Centre, Montreal, Quebec, Canada; Department of Radiology, Section of Radiation Oncology, Rady Faculty of Health Sciences, University of Manitoba, CancerCare Ma…
Förderung
- Canadian Cancer Society Research Institute
Zitieren
APA
Hou, Q., Parpia, S., Wierzbicki, M., Kundapur, V., Faria, S., Okawara, G. S., Tsakiridis, T. K., Ahmed, N., Bujold, A., Hirmiz, K., Owen, T., Leong, N., Ramchandar, K., Filion, E., Lau, H., Gabos, Z., Thompson, R., Yaremko, B., Mehiri, S., …, & Swaminath, A. (2025). Quality of Life of Stereotactic Versus Hypofractionated Radiation Therapy for Inoperable Stage I Non-Small Cell Lung Cancer: Results From the LUSTRE Trial. International Journal of Radiation Oncology*Biology*Physics. https://doi.org/10.1016/j.ijrobp.2025.11.026
Vancouver
Hou Q, Parpia S, Wierzbicki M, Kundapur V, Faria S, Okawara GS, et al. Quality of Life of Stereotactic Versus Hypofractionated Radiation Therapy for Inoperable Stage I Non-Small Cell Lung Cancer: Results From the LUSTRE Trial. International Journal of Radiation Oncology*Biology*Physics. 2025. doi:10.1016/j.ijrobp.2025.11.026
BibTeX
@article{Hou2025,
author = {Hou, Qirui and Parpia, Sameer and Wierzbicki, Marcin and Kundapur, Vijayananda and Faria, Sergio and Okawara, Gordon S and Tsakiridis, Theodoros K and Ahmed, Naseer and Bujold, Alexis and Hirmiz, Khalid and Owen, Timothy and Leong, Nelson and Ramchandar, Kevin and Filion, Edith and Lau, Harold and Gabos, Zsolt and Thompson, Robert and Yaremko, Brian and Mehiri, Selma and Louie, Alexander V and Quan, Kimmen and Levine, Mark N and Wright, James R and Whelan, Timothy J and Swaminath, Anand},
title = {Quality of Life of Stereotactic Versus Hypofractionated Radiation Therapy for Inoperable Stage I Non-Small Cell Lung Cancer: Results From the LUSTRE Trial},
journal = {International Journal of Radiation Oncology*Biology*Physics},
year = {2025},
doi = {10.1016/j.ijrobp.2025.11.026}
}
EUVIMED